Quantcast

Latest Genentech Inc. Stories

2008-10-02 18:00:06

Genentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy (PML) in a 70-year old patient who had received Raptiva(R) (efalizumab) for more than four years for treatment of chronic plaque psoriasis. The company will work with the U.S. Food and Drug Administration (FDA) to update the prescribing information for Raptiva and determine if further action is needed....

2008-09-15 21:00:09

The world's pharmaceutical giants invent and market medicines that save, prolong and vastly improve the quality of our lives. In return, we give them more money than most people can imagine. That's not entirely a bad trade, except that the highly complex nature of evaluating drugs, the ever-improving marketing savvy of the drug companies and the weakness of the Food and Drug Administration are clearly combining to tilt the deal too far on the side of profits and too little on the side of...

2008-08-29 03:00:10

WASHINGTON - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing. The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance - or cooperate with - a National Eye Institute study comparing the...

2008-08-28 09:01:23

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech, Inc. has indicated that it expects to initiate a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog antagonist, as a maintenance therapy for ovarian cancer patients in second or third complete remission. Genentech is developing GDC-0449 under a collaboration...

08437c12a373722e7aef749237ef41041
2008-08-28 09:05:00

By Kevin Freking Associated Press What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing. The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance -- or cooperate with -- a National Eye...

2008-08-14 03:00:19

Swiss pharmaceutical behemoth Roche will have to dig deeper into its pockets if it wants to own all of Genentech Inc., which rejected its $43.7 billion offer. Analysts said that's exactly what they expect Roche to do after the South San Francisco company turned down its $89-a-share tender Wednesday, The New York Times reported. One analyst, Mark Schoenebaum of Deutsche Bank, advised his clients that Genentech's tone in rejecting the offer "appears friendly." That, he said, indicates there...

2008-07-22 00:00:20

Biotechnology pioneer Genentech Inc. considered Roche Holding's $43.7 billion offer for its remaining shares Monday as investors made clear their feelings that the Swiss pharmaceutical giant should pay considerably more. But some analysts said Roche, already Genentech's majority shareholder, has leverage to keep the price for the maker of the blockbuster cancer therapy Avastin and other cancer treatments from spiraling much higher. Originally published by Staff and wire reports. (c)...

2008-06-18 09:01:18

Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, Inc. The milestone was triggered by Genentech's filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for an ADC utilizing Seattle Genetics' technology. "Genentech and our other collaborators continue to make strong progress with ADCs utilizing our technology, and we expect multiple ADC...

2006-08-29 08:24:22

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S. Food and Drug Administration has already approved Lucentis, a drug developed by U.S. firm Genentech Inc., to treat vision loss from the so-called "wet," or more severe form of age-related macular degeneration (AMD). Genentech has the commercial...

2006-08-29 05:04:54

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S. Food and Drug Administration has already approved Lucentis, a drug developed by U.S. firm Genentech Inc., to treat vision loss from the so-called "wet," or more severe form of age-related macular degeneration (AMD). Genentech has the commercial...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related